Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation and Depletion: 2011-2025

Historic Depreciation and Depletion for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $157,000.

  • Niagen Bioscience's Depreciation and Depletion fell 4.27% to $157,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $624,000, marking a year-over-year decrease of 9.43%. This contributed to the annual value of $663,000 for FY2024, which is 23.79% down from last year.
  • As of Q3 2025, Niagen Bioscience's Depreciation and Depletion stood at $157,000, which was down 0.63% from $158,000 recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Depreciation and Depletion peaked at $235,000 during Q3 2022, and registered a low of $151,000 during Q4 2024.
  • Over the past 3 years, Niagen Bioscience's median Depreciation and Depletion value was $170,000 (recorded in 2024), while the average stood at $182,364.
  • Per our database at Business Quant, Niagen Bioscience's Depreciation and Depletion rose by 13.43% in 2023 and then declined by 29.61% in 2024.
  • Over the past 5 years, Niagen Bioscience's Depreciation and Depletion (Quarterly) stood at $211,000 in 2021, then grew by 4.74% to $221,000 in 2022, then declined by 19.91% to $177,000 in 2023, then decreased by 14.69% to $151,000 in 2024, then dropped by 4.27% to $157,000 in 2025.
  • Its Depreciation and Depletion stands at $157,000 for Q3 2025, versus $158,000 for Q2 2025 and $158,000 for Q1 2025.